Time for enhancing government-led primary prevention of cervical cancer

Kyung‐Jin Min, Dong Hoon Suh, Tsukasa Baba, Xiaojun Chen, Jae‐Weon Kim, Yusuke Kobayashi, Janice S. Kwon, Myong Cheol Lim, Jung‐Yun Lee, Satoru Nagase, Jeong‐Yeol Park, Siriwan Tangjitgamol, Hidemichi WatariJournal of Gynecologic Oncology 2020 · DOI

Abstract

Cervical cancer is a preventable disease, yet its elimination remains a global challenge. Recent evidence from the Swedish nationwide registry demonstrates that human papillomavirus (HPV) vaccination provides a survival benefit, reducing the risk of invasive cervical cancer by 88% when administered before age 17. However, achieving these benefits at a population level requires "herd immunity," typically defined as at least 50% vaccination coverage. This article examines the critical role of government-led National Immunization Programs (NIPs) and highlights the barriers to high coverage in Asian nations, including misinformation and limited program scope.

The Clinical Efficacy of HPV Vaccination

The primary prevention of cervical cancer has reached a milestone with the confirmation of its real-world impact on invasive disease. A landmark study by Lei et al. using Swedish registry data showed that women vaccinated before the age of 17 experienced a dramatic 88% reduction in cervical cancer incidence compared to unvaccinated peers. This efficacy underscores the importance of early intervention. To translate these individual benefits into a public health victory, high vaccine coverage is essential to induce herd immunity, protecting even those who remain unvaccinated.

Global Adoption and the Role of NIPs

The most effective way to achieve high coverage is through robust, government-funded National Immunization Programs (NIPs). As of late 2020, the World Health Organization (WHO) reported that 110 countries—approximately 57% of the world—had integrated the HPV vaccine into their national schedules.

Global status of HPV vaccine introduction in National Immunization Programs as of October 2020 (Source: WHO).

Despite this progress, significant regional disparities persist. While countries like Australia have surpassed 80% coverage, leading to a near-total collapse in cancer rates, many Asian nations lag behind. In countries like Indonesia, the Philippines, and Singapore, coverage rates have historically hovered below 1%, far below the threshold required for herd immunity.

Regional Hurdles: Japan and South Korea

The path to high coverage is often obstructed by social and structural barriers. Japan serves as a cautionary example; following reports of rare adverse events such as complex regional pain syndrome, the Japanese government suspended its proactive recommendation for the HPV vaccine in 2013. This suspension, fueled by misinformation, is projected to result in over 67,000 preventable deaths over the next two decades.

In South Korea, the challenge is one of scope rather than sentiment. While the NIP has successfully reached 86.3% of the 12-year-old cohort (2007 birth year), the overall population coverage remains low at approximately 26%. This "patchy" immunity, restricted to narrow age groups, prevents the broader decline in cancer incidence seen in more inclusive international programs.

Economic and Technological Considerations

Beyond clinical efficacy, there is a strong economic argument for government intervention. In regions like Punjab, India, pilot programs have demonstrated that HPV vaccination is "highly cost-effective." Furthermore, the transition to nonavalent vaccines—which protect against nine strains of HPV—offers an opportunity to maximize the impact of NIPs.

Conclusion and Future Directions

To eliminate cervical cancer, governments must move beyond pilot programs and narrow age cohorts. Key recommendations include:

  • Expanding NIP Scope: Increasing the age range for eligible recipients and considering gender-neutral vaccination.
  • Countering Misinformation: Actively promoting the safety profile of vaccines to rebuild public trust, particularly in regions affected by anti-vaccine movements.
  • Infrastructure Investment: Developing national registries to track long-term outcomes and efficacy.

The tools to prevent cervical cancer exist; the challenge now lies in the political will to implement them at scale.

Summary updated

Abstract

1/5 https://ejgo.org Cervical cancer is a preventable disease. Lei et al. [1] recently demonstrated using the Swedish nationwide registry that human papillomavirus (HPV) vaccines protected not only precancerous cervical lesions but also invasive cervical cancers. In this study, the risk of cervical cancer among women who had been vaccinated <17 years of age was 88% lower than the unvaccinated population. This effective vaccination results in a survival benefit when 'herd immunity' is achieved through high vaccination coverage in a population. One systematic review and meta-analysis by Drolet et al. Vaccine coverage of the study of Lei et al. This critical role of high vaccine coverage rates in reduction of cervical cancer incidence suggest that the HPV vaccination program must be scaled to national levels.
BibTeX
@article{min2020time,
  author = {Kyung‐Jin Min and Dong Hoon Suh and Tsukasa Baba and Xiaojun Chen and Jae‐Weon Kim and Yusuke Kobayashi and Janice S. Kwon and Myong Cheol Lim and Jung‐Yun Lee and Satoru Nagase and Jeong‐Yeol Park and Siriwan Tangjitgamol and Hidemichi Watari},
  title = {{Time for enhancing government-led primary prevention of cervical cancer}},
  journal = {Journal of Gynecologic Oncology},
  year = {2020},
  doi = {10.3802/jgo.2021.32.e12},
}
Figure